Nilotinib in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or -intolerance: Update of a phase II study

被引：0
|
作者：
le Coutre, P.
Giles, F. J.
Apperley, J.
Ottmann, O. G.
Larson, R. A.
Haque, A.
Gallagher, N.
Rosti, G.
Cortes, J. E.
Kantarjian, H. M.
机构：
[1] Humboldt Univ, D-10099 Berlin, Germany
[2] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
[3] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, London, England
[4] Med Klin III, Frankfurt, Germany
[5] Univ Chicago Hosp, Chicago, IL 60637 USA
[6] Novartis Pharmaceut, E Hanover, NJ USA
[7] Orsola Malpighi Univ, Bologna, Italy
[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7050
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase II study of nilotinib, a novel tyrosine kin ase inhibitor administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who have also failed dasatinib therapy.
    Giles, Francis
    le Coutre, Philipp
    Bhalla, Kapil
    Rosti, Gianantonio
    Ossenkopplele, G. J.
    Alimena, Giuliana
    Weitzman, Aaron
    Rafferty, Teresa
    Zheng, Ming
    Kantarjian, Hagop
    BLOOD, 2006, 108 (11) : 615A - 616A
  • [42] A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with chronic myelogenous leukemia (CML) in accelerated phase (AP).
    Le Coutre, P. D.
    Ottmann, O.
    Gatterman, N.
    Larson, R.
    Rafferty, T.
    Alland, L.
    Tavorath, R.
    Giles, F.
    O'Brien, S. G.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 344S - 344S
  • [43] Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
    A Hochhaus
    M Baccarani
    M Deininger
    J F Apperley
    J H Lipton
    S L Goldberg
    S Corm
    N P Shah
    F Cervantes
    R T Silver
    D Niederwieser
    R M Stone
    H Dombret
    R A Larson
    L Roy
    T Hughes
    M C Müller
    R Ezzeddine
    A M Countouriotis
    H M Kantarjian
    Leukemia, 2008, 22 : 1200 - 1206
  • [44] Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
    Hochhaus, A.
    Baccarani, M.
    Deininger, M.
    Apperley, J. F.
    Lipton, J. H.
    Goldberg, S. L.
    Corm, S.
    Shah, N. P.
    Cervantes, F.
    Silver, R. T.
    Niederwieser, D.
    Stone, R. M.
    Dombret, H.
    Larson, R. A.
    Roy, L.
    Hughes, T.
    Mueller, M. C.
    Ezzeddine, R.
    Countouriotis, A. M.
    Kantarjian, H. M.
    LEUKEMIA, 2008, 22 (06) : 1200 - 1206
  • [45] Nilotinib isassociated with minimal cross intoleranceto imatinib in patients with imatinib-intolerant Philadelphia-positive chronic myelogenous leukemia in either chronic phase or accelerated phase
    Rosti, G.
    Hochhaus, A.
    Le Coutre, P.
    Baccarani, M.
    Bhalla, K.
    Ossenkoppele, G.
    Gattermann, N.
    Haque, A.
    Weitzman, A.
    Giles, F.
    Kantarjian, H.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 319 - 320
  • [46] Nilotinib therapy after dasatinib failure in patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC)
    Giles, Francis J.
    le Coutre, Phillip
    Bhalla, Kapil N.
    Ossenkoppele, Gert
    Alimena, Giuliana
    Haque, Ariful
    Gallagher, Neil
    Kantarjian, Hagop M.
    BLOOD, 2007, 110 (11) : 311A - 312A
  • [47] Phase II study of bortezomib (VELCADE™, formerly PS-341) for patients with imatinib-refractory chronic myeloid leukemia (CML) in chronic (CP) or accelerated phase (AP).
    Cortes, J
    Giles, F
    O'Brien, S
    Beran, M
    McConkey, D
    Wright, J
    Schenkein, D
    Patel, G
    Verstovsek, S
    Pate, O
    Talpaz, M
    Kantarjian, H
    BLOOD, 2003, 102 (11) : 312B - 313B
  • [48] Efficacy and Safety of Bosutinib (SKI-606) in Patients with Chronic Phase (CP) Ph plus Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib
    Cortes, Jorge
    Kantarjian, Hagop M.
    Kim, Dong-Wook
    Khoury, H. Jean
    Turkina, Anna G.
    Shen, Zhi-Xiang
    Brummendorf, Tim H.
    Chandy, Mammen
    Arkin, Steven
    Gambacorti-Passerini, Carlo
    BLOOD, 2008, 112 (11) : 401 - 401
  • [49] Survival advantage for patients (pts) with chronic myeloid leukemia (CML) in accelerated phase (AP) treated with imatinib.
    Cortes, J
    Talpaz, M
    O'Brien, S
    Garcia-Manero, G
    Ravandi-Kashami, F
    Giles, F
    Faderl, S
    Wierda, W
    Shan, JQ
    Rios, MB
    Kantaijian, H
    BLOOD, 2004, 104 (11) : 287A - 288A
  • [50] Homoharringtonine (HHT) plus cytarabine (Ara-C) for chronic myeloid leukemia in accelerated phase (CML-AP).
    Maloisel, F
    De Sarrazin, A
    Fohrer, C
    Rousselot, P
    Maisonneuve, H
    Lucas, P
    Campos, F
    Dufour, P
    Bergerat, JP
    BLOOD, 2001, 98 (11) : 262B - 262B
12345